Insulet Stock Beta
| GOV Stock | EUR 254.10 2.10 0.83% |
Insulet fundamentals help investors to digest information that contributes to Insulet's financial success or failures. It also enables traders to predict the movement of Insulet Stock. The fundamental analysis module provides a way to measure Insulet's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Insulet stock.
Insulet |
Insulet Company Beta Analysis
Insulet's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Insulet Beta | 0.74 |
Most of Insulet's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Insulet is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Insulet has a Beta of 0.7392. This is 14.05% lower than that of the Healthcare sector and 28.92% lower than that of the Medical Devices industry. The beta for all Germany stocks is notably lower than that of the firm.
Insulet Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Insulet's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Insulet could also be used in its relative valuation, which is a method of valuing Insulet by comparing valuation metrics of similar companies.Insulet is currently under evaluation in beta category among its peers.
As returns on the market increase, Insulet's returns are expected to increase less than the market. However, during the bear market, the loss of holding Insulet is expected to be smaller as well.
Insulet Fundamentals
| Return On Equity | 0.0089 | |||
| Return On Asset | 0.0183 | |||
| Profit Margin | 0 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 20.54 B | |||
| Shares Outstanding | 69.54 M | |||
| Shares Owned By Insiders | 0.45 % | |||
| Shares Owned By Institutions | 99.54 % | |||
| Price To Earning | 500.89 X | |||
| Price To Book | 49.00 X | |||
| Price To Sales | 16.40 X | |||
| Revenue | 1.31 B | |||
| Gross Profit | 805.6 M | |||
| EBITDA | 36.5 M | |||
| Net Income | 4.6 M | |||
| Cash And Equivalents | 316.37 M | |||
| Cash Per Share | 5.30 X | |||
| Total Debt | 1.37 B | |||
| Debt To Equity | 272.60 % | |||
| Current Ratio | 4.36 X | |||
| Book Value Per Share | 6.85 X | |||
| Cash Flow From Operations | (68.1 M) | |||
| Earnings Per Share | 0.22 X | |||
| Price To Earnings To Growth | 3.32 X | |||
| Target Price | 290.41 | |||
| Number Of Employees | 2.6 K | |||
| Beta | 0.74 | |||
| Market Capitalization | 18.08 B | |||
| Total Asset | 2.25 B | |||
| Z Score | 7.8 | |||
| Net Asset | 2.25 B |
About Insulet Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Insulet's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Insulet using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Insulet based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Insulet Stock
When determining whether Insulet is a strong investment it is important to analyze Insulet's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insulet's future performance. For an informed investment choice regarding Insulet Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Insulet Stock please use our How to Invest in Insulet guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.